Drug Trial Radar · NCT04480853
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
14
Actual
Start
Oct 12, 2020
Primary completion
Oct 15, 2026
Study completion Nov 15, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.
Conditions
- Multiple Sclerosis
Interventions
FingolimodDrug
Fingolimod 0.5 mg QD, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events of Special Interest(AESI)Time frame: First Dose Observation on the first day of taking findolimod
- Number of Adverse Events of Special Interest (AESI)Time frame: Baseline up to 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Kaohsiung City, Taiwan
Novartis Investigative Site
Taichung, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.